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Abstract 
Distant metastasis to specific target organs is responsible for over 90% of breast cancer‑related deaths, but the 
underlying molecular mechanism is unclear. Mounting evidence suggests that the interplay between breast cancer 
cells and the target organ microenvironment is the key determinant of organ‑specific metastasis of this lethal disease. 
Here, we highlight new findings and concepts concerning the emerging role of the tumor microenvironment in 
breast cancer metastasis; we also discuss potential therapeutic intervention strategies aimed at targeting compo‑
nents of the tumor microenvironment.
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Background
In terms of its molecular characteristics and clinical phe-
notypes, breast cancer is a highly heterogeneous malig-
nancy. Like other solid tumor cells, breast cancer cells 
tend to metastasize to distant organs, such as the lung [1, 
2], liver [2], bone [3], and brain [4], through local invasion 
and lymphatic and vascular dissemination. Metastasis is 
a continuous and multi-step biological process, in which 
a subpopulation of cancer cells with highly invasive and 
metastatic potential depart from their original locations, 
degrade the extracellular matrix (ECM), intravasate into 
the blood or lymphatic vessels, survive in the circulation, 
and extravasate to and colonize new terrain in the target 
organs [5, 6]. Although it is generally believed that breast 
cancer metastasis is a manifestation of late-stage and 
advanced disease, emerging evidence suggests that breast 
cancer cells can spread systemically at an early disease 
stage regardless of primary tumor size [7].
Distant metastasis attributes to approximately 90% 
of breast cancer-related deaths; as such, its underly-
ing mechanisms are of intense interest and have been 
investigated extensively. Recently, several laboratories 
screened and identified a batch of breast cancer metas-
tasis-related genes using well-established animal mod-
els of metastatic breast cancer in combination with 
high-throughput genomic analysis (Table  1). For exam-
ple, it has been shown that secreted protein acid and 
rich in cysteine (SPARC), vascular cell adhesion mol-
ecule 1 (VCAM1), matrix metalloproteinase 2 (MMP2), 
and interleukin-13 receptor subunit α2 (IL-13Rα2) are 
involved in breast cancer lung metastasis [1], whereas 
interleukin-11 (IL-11) and connective tissue growth fac-
tor (CTGF) play a key role in breast cancer bone metas-
tasis [3]. In addition, ST6 N-acetylgalactosaminide 
α-2,6-sialyltransferase 5 (ST6GALNAC5) mediates breast 
cancer brain metastasis [4]. Yet despite these remark-
able advances, the precise molecular mechanisms behind 
breast cancer invasion and metastasis have not been fully 
delineated, therefore hampering the design of effective 
therapeutic strategies.
Since Paget proposed the well-known “seed and soil” 
theory of cancer metastasis in 1889 [8], accumulating 
evidence has shown that the interaction between breast 
cancer cells and the surrounding microenvironment is 
a determinant for breast cancer organ-specific metas-
tasis [9]. The tumor microenvironment comprises stro-
mal cells, bioactive molecules secreted by both tumor 
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and stromal cells, ECM, and the lymphatic and vascular 
systems [10]. Stromal cells include immune cells, can-
cer-associated fibroblasts (CAFs), pericytes, and mesen-
chymal stem cells (Table 2). Secreted bioactive molecules 
by both tumor and stromal cells include growth factors, 
cytokines, chemokines, and exosomes [2, 10–13]. On the 
one hand, breast cancer cells educate the surrounding 
microenvironment to facilitate their invasion, survival, 
and growth in the manner of autocrine and paracrine. On 
the other hand, the tumor microenvironment adversely 
affects the invasive and metastatic potential of breast 
cancer cells. However, how these processes are regulated 
remains unclear.
Here, we highlight new findings and emerging con-
cepts regarding the role of the tumor microenvironment 
in breast cancer metastasis. Furthermore, we discuss the 
possibility of developing effective treatments by targeting 
components of the tumor microenvironment.
Breast cancer cell features and breast cancer 
metastasis
Epithelial‑to‑mesenchymal transition
Epithelial-to-mesenchymal transition (EMT) is a com-
plex biological process in which epithelial cells are 
transited to a mesenchymal cell phenotype by genetic 
and epigenetic mechanisms [14–16]. The main feature 
of EMT is that epithelial cells lose phenotypes of cell 
polarity and cell–cell adhesion due to decreased or lost 
expression of cell adhesion molecules, such as E-cadherin 
(E-cad), while gaining a mesenchymal cell phenotype 
with highly migrative, invasive, and anti-apoptotic poten-
tial [10, 14–16]. The EMT program that is activated by 
several transcription factors, such as Snail, Slug, Twist, 
zinc finger E-box-binding homeobox  1/2 (ZEB1/2), and 
sex-determining region Y-box 4 (SOX4), plays a key role 
in multiple physiological processes, including embryonic 
development, chronic inflammation, and wound healing 
[10]. Interestingly, dysregulation of these transcription 
factors and related signaling pathways are implicated in 
breast cancer invasion and metastasis via activating the 
EMT program [17, 18].
Although many studies have demonstrated the criti-
cal roles of EMT in breast cancer metastasis, emerging 
evidence has shown that EMT may not be a prerequisite 
for triggering breast cancer metastasis. A case in point 
is paired related homeobox 1 (Prrx1), which is an EMT-
inducing factor but inhibits breast cancer cell metasta-
sis [19]. In support of these findings, Fischer et  al. [20] 
found that only a small fraction of tumor cells undergo 
Table 1 Breast cancer metastasis-regulated genes
SPARC, secreted protein acid and rich in cysteine; VCAM1, vascular cell adhesion 
molecule 1; MMP2, matrix metallopeptidase 2; IL-13Rα2, interleukin-13 
receptor subunit alpha-2; Par6, partitioning-defective protein 6; BCAR4, breast 
cancer anti-estrogen resistance 4; TNC, tenascin C; CXCL12, C–X–C motif 
chemokine ligand 12; CXCR4, C–X–C motif chemokine receptor 4; CCL2, C–C 
motif chemokine ligand 2; SERPINE2, serpin family E member 2; SLPI, secretory 
leukocyte peptidase inhibitor; miR, microRNA; IL-11, interleukin-11; CTGF, 
connective tissue growth factor; LOX, lysyl oxidase; JAG1, Jagged 1; PDK1, 
pyruvate dehydrogenase kinase 1; ST6GALNAC5, ST6 N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 5; NRP2, neuropilin 2
Target organ Function(s) in breast 
cancer metastasis
Gene Reference(s)
























Liver Promotion αVβ5 [2]
PDK1 [30]
Brain Promotion ST6GALNAC5 [4]
miR‑19a [78]
Lymph node Promotion CXCL12/CXCR4 [73]
NRP2 [81]
Table 2 Stromal cells in breast cancer metastasis




 Macrophages Promotion [40–44]
 Neutrophils Promotion/suppression [45, 46, 96, 97]
 T cells Promotion/suppression [44, 46, 49]




Pericytes Suppression [54, 55]
Mesenchymal stem cells Promotion [26, 56]
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the EMT process in primary breast tumors, and lung 
metastatic cells still maintain epithelial cell characteris-
tics. Moreover, suppression of EMT by overexpression 
of microRNA-200 (miR-200) does not affect the devel-
opment of lung metastasis of breast cancer, but it does 
significantly enhance cellular response to chemotherapy 
[20]. These results suggest that EMT is not required 
for lung metastasis. Considering these emerging con-
troversial data, the functional and mechanistic roles 
of EMT in breast cancer metastasis need to be further 
characterized.
Cell polarity
Cell polarity is referred to as the asymmetry of cell mor-
phology and the function and distribution of proteins. 
Cell polarity is tightly regulated by the polarity protein 
complex and has a significant role in cell proliferation, 
division, and migration and in tissue morphogenesis. The 
development of epithelial tumors is frequently accompa-
nied by the loss of cell polarity, which leads to invasion 
and metastasis. For example, polarity protein partition-
ing defective 3 (Par3) is frequently down-regulated in 
breast cancer and can suppress mammary tumorigen-
esis and metastasis by inhibiting the expression of ECM-
degrading enzyme matrix metalloproteinase 9 (MMP9) 
and the activation of the oncogenic JAK/STAT3 pathway 
[21, 22]. Moreover, Par3 loss is associated with aberrant 
activation of proto-oncogene ErbB2, a key regulator of 
the invasion and metastasis of breast cancer [22]. In addi-
tion, Par6-mediated cell polarity signaling pathways also 
play an important role in breast cancer metastasis [23]. 
In breast cancer xenograft models, inhibition of Par6 
induces the formation of epithelial structure and inhib-
its breast cancer lung metastasis [23]. Furthermore, tran-
scription factor ZEB1 can inhibit the expression of cell 
polarity gene lethal giant larvae homolog 2 (Lgl2), which 
is critical for maintenance of epithelial cell phenotype 
and is often down-regulated in breast cancer [24]. Thus, 
ZEB1-mediated down-regulation of Lgl2 may play a role 
in breast cancer metastasis [24].
Breast cancer stem cells
In 2003, Al-Hajj et  al. [25] successfully isolated breast 
cancer stem cells (BCSCs) from breast cancer specimens; 
since then, BCSCs have been considered an important 
factor for breast cancer metastasis and therapeutic resist-
ance. Recently, Cuiffo et  al. [26] showed that language 
development-associated gene forkhead box p2 (FOXP2) 
inhibits the amplification of BCSCs and the initiation 
and metastasis of breast cancer. Induction of miR-199a 
expression by mesenchymal stem cells (MSCs) increases 
the stemness of BCSCs through transcriptional repres-
sion of FOXP2 [26]. In addition, transcription factors 
Slug and Sox9 collaboratively maintain the stem cell state 
of BCSCs, and co-expression of these two transcription 
factors enhances the tumorigenic and metastatic abil-
ity of breast cancer [27]. Transcription co-activator with 
PDZ-binding motif (TAZ), a main downstream effector 
of the Hippo pathway, is highly expressed in BCSCs and 
poorly differentiated breast cancer cells, and is critical 
for the maintenance of self-renewal of BCSCs, as well as 
breast cancer growth, metastasis, and resistance to chem-
otherapy [28]. Therefore, further studies to elucidate the 
mechanisms of BCSCs in the progression and metastasis 
of breast cancer are crucial for the development of novel 
targeted therapeutic strategies.
Tumor metabolism
According to the Warburg effect, most tumor cells 
increase aerobic glycolysis to reduce the levels of mito-
chondrial oxidative phosphorylation. To compensate for 
the lack of adenosine triphosphate (ATP), cancer cells 
increase glucose uptake and utilization. Recently, Fong 
et  al. [29] found that breast cancer-secreted miR-122 
suppresses glucose uptake of niche cells by down-regu-
lating the glycolytic enzyme pyruvate kinase to enhance 
nutrient availability in the pre-metastatic niche and, 
thus, facilitate metastasis. In addition, Dupuy et  al. [30] 
showed that different metabolic programs used by breast 
cancer cells determine the specificity of target organ of 
metastasis; they also showed that this process is con-
trolled by pyruvate dehydrogenase kinase 1 (PDK1). In 
this context, unlike bone or lung metastatic cells, liver 
metastatic breast cancer cells exhibit a unique metabolic 
program, characterized by increased hypoxia inducible 
factor 1α (HIF1α) activity and enhanced expression of its 
target, PDK1 [30].
Non‑coding RNAs
Non-coding RNAs are the RNA molecules that are not 
translated into proteins. Of these, miRs are a group of 
evolutionarily conserved short (20–24 nucleotides) non-
coding RNAs that are involved in post-transcriptional 
regulation of gene expression. Emerging evidence sug-
gests that the abnormal expression of miRs can either 
promote or suppress breast cancer metastasis. miR-10b 
is highly expressed in metastatic breast cancer cells and 
promotes cell migration, invasion, and metastasis [31]. 
Ma et al. [31] have shown that Twist transcriptionally up-
regulates miR-10b, which, in turn, suppresses the expres-
sion of the metastasis-suppressing gene homeobox D10 
(HOXD10) and up-regulates the expression of the metas-
tasis-promoting gene Rho.
Not surprisingly, some miRs have been shown to func-
tion in breast cancer as metastasis suppressors. For 
example, miR-34a suppresses osteoclast formation and 
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bone metastasis by inhibiting the expression of osteoclas-
togenesis-inducing factor and transforming growth fac-
tor β (TGFβ)-induced factor 2 (TGIF2) [32]. Endogenous 
miR-126 is down-regulated in primary breast cancer tis-
sues [33] and can suppress endothelial cell recruitment, 
angiogenesis, and metastatic formation by modulat-
ing the expression of insulin-like growth factor-binding 
protein 2 (IGFBP2), C-Mer tyrosine kinase (MERTK), 
and phosphatidylinositol transfer protein, cytoplasmic 1 
(PITPNC1) [34]. In addition, miR-126/miR-126* directly 
inhibits chemokine C–X–C motif ligand 12 (CXCL12) 
and indirectly suppresses chemokine C–C motif ligand 
2 (CCL2) in a CXCL12-dependent manner, thereby 
blocking the recruitment of MSCs and inflammatory 
monocytes to the tumor microenvironment and reduc-
ing the lung metastatic potential of breast cancer [35]. 
In addition to miR-126, miR-335 is also down-regulated 
in primary breast tumors and suppresses breast can-
cer metastasis by targeting progenitor cell transcription 
factor SOX4 and extracellular matrix component tenas-
cin C [33]. miR-708 is significantly down-regulated in 
metastatic triple-negative breast cancer and is epigeneti-
cally silenced by enhancer of zeste 2 polycomb repres-
sive complex 2 subunit (EZH2), which is a core subunit 
of the polycomb repressive complex 2 (PRC2) [36]. Con-
sistently, induction of miR-708 blocks lung metastasis of 
triple-negative breast cancer by, at least in part, inhibit-
ing endoplasmic reticulum calcium-regulatory protein 
neuronatin [36].
Long non-coding RNA (lncRNA) is another type of 
non-coding RNA that is longer than 200 nucleotides. 
lncRNA was initially considered a byproduct of RNA 
polymerase II-mediated transcription without any bio-
logical functions. Recent studies showed that lncRNAs 
play important roles in the progression and metasta-
sis of breast cancer [37, 38]. For example, the lncRNA 
breast cancer anti-estrogen resistance 4 (BCAR4) is 
highly up-regulated in advanced breast cancer patients 
and promotes breast cancer metastasis by activating a 
noncanonical hedgehog/glioma-associated oncogene 
family zinc finger 2 (GLI2) transcriptional program that 
promotes cell migration [37]. In contrast, nuclear factor 
kappa B (NF-κB)-interacting lncRNA (NKILA) has been 
shown to suppress breast cancer growth and metastasis 
induced by overactivation of NF-κB signaling which is 
caused by various inflammatory stimuli [38]. Consist-
ently, breast cancer patients who have low expression of 
NKILA have a poor prognosis [38].
Stromal cells and breast cancer metastasis
Immune cells
In each step of the metastatic cascade, cancer cells 
are exposed to various types of immune cells, such as 
macrophages, lymphocytes, and monocytes, which can 
recognize them and regulate their growth and progres-
sion [39]. For example, clinical and experimental evi-
dence has shown that macrophages play important roles 
in breast cancer growth, invasion, and metastasis [40, 
41]. First, macrophages create an inflammatory microen-
vironment during the initiation phase to promote tumor 
growth [40, 41]. Second, macrophages stimulate angio-
genesis, tumor cell invasion, and migration and suppress 
anti-tumor immunity as tumors progress to malignancies 
[40, 41]. Third, macrophages promote tumor cell extrava-
sation, survival, and subsequent growth at the meta-
static sites [40, 41]. Fourth, VCAM1 is highly expressed 
in breast cancer cells and recruits tumor-associated 
macrophages (TAMs) to the tumor microenvironment, 
triggering Akt activation in cancer cells and protect-
ing cancer cells from cytokine-induced apoptosis [42]. 
Fifth, the interplay between macrophages and mesenchy-
mal-like breast cancer cells is crucial for breast cancer 
metastasis [43]. In this context, mesenchymal-like breast 
cancer cells secrete granulocyte–macrophage colony-
stimulating factor (GM-CSF) to promote the transfor-
mation of macrophages into TAMs. In turn, chemokine 
CCL18 secreted by TAMs induces mesenchymal-like 
breast cancer cells to activate the EMT program, thus 
creating a positive feedback loop between macrophages 
and mesenchymal-like breast cancer cells to promote 
invasion and metastasis of breast cancer cells [43]. Inhi-
bition of GM-CSF or CCL18 significantly reduces breast 
cancer metastasis [43]. Finally, CD11 antigen-like fam-
ily member B (CD11b)-positive, interferon gamma 
receptor 1 (Gr1)-negative, and cell surface glycoprotein 
F4/80-positive  (CD11b+Gr1−F4/80+) tumor-associated 
macrophages trigger metastasis of breast cancer via acti-
vation of the epidermal growth factor receptor (EGFR) 
signaling pathway [44]. Together, these findings indi-
cate that macrophages play a key role in breast cancer 
metastasis.
Neutrophils are the most common immune cells in the 
body, but their role in breast cancer metastasis remains 
controversial. Before metastatic breast cancer cells arrive 
in the lung tissue, neutrophils are gathered at the pre-
metastatic site in the lung and produce leukotrienes, 
which recruit highly tumorigenic breast cancer cells to 
the lung and thereby promote the seeding and coloniza-
tion of breast cancer cells [45]. Consistently, inhibition of 
leukotriene-producing enzyme arachidonate 5-lipoxyge-
nase (Alox5) blocks neutrophil-mediated lung metastasis 
[45]. In addition, tumor-induced neutrophils promote the 
migration of breast cancer by inhibiting cytotoxic  CD8+ 
T lymphocytes [46]. However, other studies showed that 
neutrophils can inhibit breast cancer metastasis by pro-
ducing hydrogen peroxide and nitric oxide [47, 48].
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T cells are the main component of lymphocytes 
with different subgroups, and their role in breast can-
cer metastasis is complicated. CD4-positive T lym-
phocytes promote lung metastasis of breast cancer by 
directly enhancing the function of tumor-associated 
 CD11b+Gr1−F4/80+ macrophages [44]. Interleukin-17 
(IL-17)-producing γδ T cells and neutrophils synergisti-
cally promote pulmonary and lymph node metastasis 
[46]. The underlying mechanism is that interleukin-1β 
(IL-1β) enhances the expression of IL-17 in γδ T cells, 
resulting in granulocyte colony-stimulating factor 
(G-CSF)-dependent expansion and polarization of neu-
trophils in mice with breast cancer. This kind of tumor-
induced neutrophils suppress the function of cytotoxic 
 CD8+ T lymphocytes, which limit the establishment of 
metastasis [46]. Additionally, tumor-infiltrating regula-
tory T cells promote breast cancer metastasis by stimu-
lating the receptor activator of the nuclear factor kappa B 
ligand (RANKL) signaling pathway [49].
Natural killer (NK) cells are major effector cells of the 
innate immune system. NK cells are enabled to recog-
nize and eliminate early malignant cells, thus preventing 
breast cancer tumorigenesis and metastasis [50]. Soluble 
MHC class I chain-related protein A (MICA) and MICB, 
two ligands of NK cell receptor D (NKG2D), can activate 
NK cells after binding NKG2D and have the function of 
immune surveillance. Interestingly, breast cancer stem 
cells decrease the expression of MICA and MICB, thus 
escaping from NK cell-mediated cytotoxicity and pro-
moting metastasis [51].
Cancer‑associated fibroblasts and pericytes
Cancer-associated fibroblasts are the most important 
host cells in the tumor microenvironment. In breast can-
cer, CAFs play a central role in the tumor microenviron-
ment since they promote angiogenesis, ECM remodeling, 
metabolic reprogramming, invasion and metastasis, and 
therapeutic resistance [52]. For example, CAF-derived 
CXCL12 and insulin-like growth factor 1 (IGF1) can pro-
mote the survival and outgrowth of highly invasive and 
metastatic triple-negative breast cancer cells in the bone 
marrow [53].
Pericytes are a kind of cells surrounding capillary 
and venous endothelial cells. Recent studies showed 
that pericytes in the microenvironment inhibit the 
metastatic potential of breast cancer cells [54, 55]. 
Depletion or pharmacological inhibition of pericytes 
is associated with increased hypoxia, EMT, and proto-
oncogene Met activation [54]. Other studies showed 
that inhibition of the function of pericytes increases 
lung metastasis of hypoxic breast cancer cells by acti-
vating the angiopoietin-2 (ANG2) signaling pathway 
[55].
Mesenchymal stem cells
Mesenchymal stem cells are the progenitors of stromal 
cells in the tumor microenvironment, contributing to 
the formation of tumor-associated stroma and metas-
tasis [26, 56]. Recently, Karnoub et  al. [56] showed that 
bone marrow-derived human MSCs can enhance the 
metastatic potential of human breast cancer cells. The 
underlying mechanism for these observations is that 
MSC-secreted chemokine CCL5 acts in a paracrine man-
ner on breast cancer cells to enhance their motility, inva-
sion, and metastasis [56]. In addition, Chaturvedi et  al. 
[57] showed that MSCs were recruited to the primary 
breast cancer tissues to promote lymph node and lung 
metastases. Moreover, miR-126/miR-126* reduces the 
lung metastatic potential of breast cancer by inhibiting 
the expression of CXCL12, thereby blocking the recruit-
ment of MSCs to the tumor ECM [35]. These studies sug-
gest that the interaction of breast cancer cells and MSCs 
in the microenvironment plays a key role in metastasis of 
breast cancer. Therefore, MSCs are expected to be a key 
target for the inhibition of breast cancer metastasis.
Secreted bioactive molecules by tumor 
and stromal cells and breast cancer metastasis
Cytokines
Transforming growth factor β is a multifunctional 
cytokine that plays a dual role in cancer development. 
TGFβ acts as a tumor suppressor in the initial stage of 
tumorigenesis but as a metastasis promoter in advanced 
cancers [58, 59]. TGFβ produced by breast cancer cells 
and stromal cells through an autocrine or paracrine 
manner promotes breast cancer metastasis via multi-
ple pathways. For example, the TGFβ-Smad pathway 
induces the expression of interleukin-11 (IL-11), connec-
tive tissue growth factor (CTGF) [3], angiopoietin-like 
4 (ANGPTL4) [60], and cut-like homeobox  1 (CUTL1) 
[61] to promote breast cancer invasion and metastasis. 
Furthermore, TGFβ forms a complex with mutant p53 
and Smad to promote breast cancer cell migration, inva-
sion, and metastasis by inhibiting tumor suppressor pro-
tein p63-mediated signaling pathways [58]. Consistently, 
lysine-specific demethylase 1 (LSD1) and tumor suppres-
sor gene deleted in liver cancer 1 (DLC1) suppress breast 
cancer invasion and metastasis by inhibiting the TGFβ 
pathway [62, 63].
In addition to TGFβ, cytokine tumor necrosis factor 
α (TNFα) also induces breast cancer cell migration and 
invasion by enhancing the stability of Snail, which is a 
major transcription factor governing the EMT program 
[16, 64]. The underlying mechanism for this event is that 
TNFα induces the expression of COP9 signalosome 2 
(CSN2) in a NF-κB-dependent manner. In turn, CSN2 
inhibits the ubiquitination and degradation of Snail to 
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increase its stability [64]. Interestingly, the release of 
TNFα from macrophages is regulated by serglycin, which 
is a proteoglycan that is highly expressed in [65] and con-
stitutively secreted by breast cancer cells [66]. Emerg-
ing evidence suggests that elevated levels of serglycin 
can enhance breast cancer cell growth, migration, and 
invasion [65]. In a MMTV-PyMT-driven mouse model, 
genetic ablation of serglycin blocked lung metastasis of 
breast cancer [67]. In addition, serglycin can bind to cell 
surface adhesion molecule CD44 and mediates cell–cell 
interactions, cell adhesion, and cell migration in human 
cancers [68].
Chemokines
Chemokines are a family of small cytokine-like molecules 
that control a wide variety of biological and pathologic 
processes, such as immune responses, viral infection, 
and cancer metastasis [69]. By binding to specific recep-
tors on the membrane of the target cells, chemokines 
can recruit immune cells to the tumor microenviron-
ment, thus regulating immune surveillance, angiogenesis, 
invasion, and metastasis [70]. To date, approximately 50 
chemokines and 20 chemokine receptors have been iden-
tified. According to the spacing of their first two cysteine 
residues, chemokines can be divided into at least four 
families: C, CC, CXC, and CX3C [71]. CXC chemokines 
mainly act on neutrophils, whereas C, CC, and CX3C 
chemokines mainly regulate monocytes, macrophages, 
and lymphocytes [72].
Since Muller et  al. [73] first reported in 2001 that the 
chemokine–chemokine receptor pathway was involved 
in the metastasis of breast cancer, the functional roles of 
chemokines and chemokine receptors in breast cancer 
metastasis have been extensively investigated (Table  3). 
For example, CCL2 produced by breast cancer cells and 
stromal cells recruits CC chemokine receptor 2 (CCR2)-
positive inflammatory monocytes to the lungs; then these 
inflammatory monocytes secrete vascular endothelial 
growth factor to promote breast cancer cell extravasation 
and lung metastasis [74]. Thus, inhibition of CCL2–CCR2 
signaling blocks lung metastasis of breast cancer [74]. In 
addition, TAMs produce CCL18; binding of CCL18 to its 
specific receptor PITPNM family member 3 (PITPNM3) 
facilitates breast cancer metastasis through activation of 
intracellular calcium signal [13]. Similarly, CXCL12 pro-
duced by CAFs mediates bone metastasis of triple-neg-
ative breast cancer [53]. In addition, human epidermal 
growth factor receptor 2 (HER2) enhances the expression 
of C–X–C motif chemokine receptor 4 (CXCR4), which 
is required for HER2-mediated invasion and metastasis 
of breast cancer [75]. Moreover, binding of bone marrow-
derived CXCL12 to its receptor CXCR4 can activate Akt, 
thus promoting breast cancer bone metastasis [76].
Exosomes
Exosomes are small extracellular vesicles secreted to the 
extracellular environment by tumor cells and stromal 
cells and play key roles in cell–cell communications [77]. 
Recent studies showed that fibroblast-secreted exosomes 
promote the migration of breast cancer cells via Wnt-
planar cell polarity (PCP) signaling [77]. Interestingly, 
tumor-derived exosomes determine organotropic 
metastasis in breast cancer [2]. In this context, exoso-
mal integrins α6β4 and α6β1 are associated with lung 
metastasis, whereas exosomal integrin αvβ5 is linked to 
liver metastasis of breast cancer [2]. In addition, brain 
astrocyte-secreted exosomes carrying miR-19 regulate 
brain metastases of breast cancer by down-regulating the 
expression of tumor suppressor gene phosphatase and 
tensin homolog (PTEN) [78].
The lymphatic and vascular system and breast 
cancer metastasis
As mentioned earlier, breast cancer metastasis requires 
that primary tumor cells possess the ability to intrava-
sate into the blood or lymphatic vessels and extravasate 
into and colonize secondary sites [79]. Vascular mim-
icry contributes to not only vasculature of primary 
tumors but also metastasis to distant organs. Recently, 
Wagenblast et  al. [79] showed that the secreted pro-
teins serpin family E member 2 (SERPINE2) and secre-
tory leukocyte peptidase inhibitor (SLPI) are primary 
regulators of vascular mimicry, and overexpression of 
SERPINE2 and SLPI is closely related to lung metastasis 
of breast cancer. In addition, vascular remodeling fac-
tors, including epiregulin, cyclooxygenase 2 (COX2), 
MMP1, and MMP2, can promote breast cancer lung 
metastasis through facilitating the release of tumor cells 
into the circulation system and breaching lung capillar-
ies by circulating tumor cells [80]. Neuropilin 2 (NRP2) 
can modulate lymphangiogenesis, but its relationship 
with the metastasis of breast cancer is unclear. A recent 
Table 3 Breast cancer metastasis-associated chemokines 
and their receptors
CCL C–C motif chemokine ligand, CCR C–C motif chemokine receptor, CXCL 
C–X–C motif chemokine ligand, CXCR C–X–C motif chemokine receptor, PITPNM3 
phosphatidylinositol transfer protein membrane-associated 3







CXCL12 CXCR4 [35, 73, 76]
CXCL8 CXCR1/2 [98]
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study has shown that inhibition of NRP2 disrupts vas-
cular endothelial growth factor C-induced lymphatic 
endothelial cell migration, reduces tumor lymphangio-
genesis, and inhibits metastasis to sentinel lymph nodes 
and distant organs by delaying the departure of tumor 
cells from the primary tumor [81]. These findings indi-
cate that NRP2 is an attractive target for modulating 
metastasis.
Hypoxic microenvironment
Mammary tumor cells are always under a hypoxic micro-
environment due to abnormal proliferation of cancer 
cells as well as dysregulation of vasculature structure 
and function. Hypoxia-inducible factor (HIF), composed 
of α and β subunits, is a master regulator of the hypoxic 
response. HIF-mediated adaption to hypoxia is mainly 
through transcriptional regulation of its downstream 
target genes that are involved cellular metabolism, angio-
genesis, cell migration and invasion, autophagy, and cell 
death [47]. One of these downstream targets is lysine 
oxidase (LOX), which can stabilize ECM by oxidizing 
amino acid residues of collagen and elastin. Recent stud-
ies showed that multiple hypoxia-HIF signaling path-
ways promote breast cancer metastasis by inducing the 
expression of LOX [48, 82, 83]. LOX is highly expressed 
in hypoxic breast cancer cells and related to the invasive 
and metastatic potential of breast cancer by modulating 
focal adhesion kinase (FAK) activity and cell-ECM adhe-
sion [83]. In addition, LOX secreted by hypoxic cells reg-
ulates the bone metastasis of estrogen receptor-negative 
breast cancer [48]. Moreover, LOX is important for the 
formation of the pre-metastasis microenvironment [82]. 
In this context, LOX is accumulated at the metastatic 
target organs and cross-linked with type IV collagen in 
basement membrane. Bone marrow-derived cells adhere 
to the cross-linked type IV collagen to promote the gen-
eration of MMP2, which, in turn, facilitates the degrada-
tion of collagen, thereby recruiting metastatic tumor cells 
to colonize the target organs [82].
Given the key role of HIF in breast cancer metastasis, 
upstream signals that regulate HIF could be involved in 
breast cancer metastasis. One case in point is SHARP1, 
also known as basic helix-loop-helix family member E41 
or differentiated embryonic chondrocyte expressed gene 
2, which suppresses the invasion and metastasis of triple-
negative breast cancer by promoting the degradation 
of HIF1α via mediating its interaction with proteasome 
[84]. SHARP1 is also regulated by a metastasis suppres-
sor gene, p63 [84].
Conclusions and perspectives
Breast cancer metastasis is the result of the interplay 
between tumor cells and the surrounding microen-
vironment, which is regulated by complex molecular 
networks. Although much progress has been made in 
understanding this process, effective therapeutic strat-
egies against breast cancer metastasis are still lacking. 
One reason for this is the lack of suitable model sys-
tems that would enable us to fully reveal the underlying 
mechanisms.
Evidence is mounting that trophoblast invasion of the 
maternal endometrium during embryo implantation and 
cancer invasion of host tissues share striking similarities 
in numerous biological processes, such as cell migration, 
invasion, angiogenesis, and immune escape [85–88]. 
However, unlike unlimited tumor invasion and metasta-
sis, embryo implantation is considered a natural model 
of successfully controlled tissue invasion [89, 90], which 
is strictly regulated through a delicate crosstalk between 
trophoblasts and the maternal endometrial microen-
vironment [87, 91–93]. Thus, unraveling the role of the 
maternal endometrial microenvironment in controlling 
trophoblast invasion during embryo implantation may 
provide new perspectives for understanding the molec-
ular mechanisms of breast cancer metastasis and for 
developing novel therapeutic strategies for metastatic 
disease.
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